Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life

OpuholiŽenskoj Reproduktivnoj Sistemy

E. D. Pashanov¹  S. A. Shcheltsyna²  E. A. Ronina²  I. A. Korneyeva²  E. G. Novikova² 

[1] Medical Department, GlaxoSmithKline, Moscow;P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies;

关键词: ovarian cancer;    recurrence;    topotecan;    efficacy;    quality of life;   

DOI  :  10.17650/1994-4098-2010-0-2-53-58

来源: DOAJ

【 摘 要 】

The main goals of the study were to evaluate the efficacy and safety of intravenous topotecan (Hycamtin) used in a dose of 4 mg/m2 on days 1, 8, and 15 of a 28-day course of therapy in patients with recurrent ovarian cancer. The study revealed a number of benefits from use of topotecan in patients with this diagnosis.

【 授权许可】

Unknown